Quantitative assessment of innate myeloid cells in myelofibrosis: insights into myeloid and plasmacytoid dendritic cell depletion and disease progression Authors: Nathália Aparecida Cavalcante Silva, Fábio Pinotti Guirao, Míriam Cristina Rodrigues Barbosa, Diego Alonso Olavarría Bernal, Laura Coutinho Vassalli, Alex Freire Sandes Published: 2025 ABSTRACT AbstractMyelofibrosis (MF) is a myeloproliferative neoplasm characterized by bone marrow fibrosis, abnormal hematopoiesis, and extramedullary hematopoiesis. Abnormalities of the tumor microenvironment and immune system may be involved in the MF physiopathology and progression, particularly affecting innate myeloid cells (IMCs) such as myeloid dendritic cells (mDCs), plasmacytoid dendritic cells (pDCs) and monocytes. This study aims to quantitatively assess these cell populations in MF patients and their association with clinical outcomes. A cohort of 21 MF patients from the Universidade Federal de São Paulo was analyzed. Peripheral blood samples were evaluated using flow cytometry to quantify pDCs and monocytic subpopulations, including classical, intermediate, and non-classical monocytes. Comparative analyses were conducted with 12 healthy controls. MF patients exhibited a significant reduction in both the relative and absolute numbers of circulating mDCs and pDCs compared to healthy controls. The pDC reduction was more pronounced in patients with grade 3 fibrosis, anemia and splenomegaly. While total monocyte percentages were slightly lower in MF patient, the distribution of monocytic subpopulations showed no significant differences between groups. Patients with JAK2 mutations demonstrated higher concentrations of intermediate monocytes. The findings reveal a remarkable depletion of pDCs in MF patients, particularly those with advanced clinical manifestations such as anemia and splenomegaly. This study highlights the potential role of dendritic cells as biomarkers for disease severity and progression in MF. Further research is needed to elucidate the functional implications of these cells and their interactions within the MF microenvironment, potentially guiding new diagnostic and therapeutic strategies.Keywords: Myelofibrosis, Plasmacytoid dendritic cells, Myeloid dendritic cells, Monocytes, Innate myeloid cells, JAK2 mutation, Anemia, Splenomegaly, Flow cytometry Introduction Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by the abnormal proliferation of the megakaryocytic and granulocytic lineages, progressive marrow fibrosis, and extramedullary haematopoiesis [1]. In advanced phases, this disorder disrupts the normal production of blood cells, leading to a plethora of clinical manifestations, including anemia, splenomegaly, and systemic symptoms. The pathophysiology of MF is complex, involving mutations in several genes that result in the activation of the JAK/STAT signalling pathway [2, 3]. These mutations include JAK2, CALR, and MPL, which trigger the clonal multiplication of myeloid progenitor cells and suppress normal hematopoietic lineages [4]. Innate myeloid cells (IMCs) are crucial for the initiation and regulation of immune responses, acting as a bridge between innate and adaptive immunity. Recent advances have highlighted the significance of the tumor microenvironment and the immune system in the progression of myeloid neoplasms, particularly the role of IMCs such as monocytes, macrophages, plasmacytoid dendritic cells (pDCs) and myeloid dendritic cells (mDCs). Several studies have shown that bone marrow increase of pDCs can be observed in association with acute myeloid leukemia with RUNX1 mutation [5, 6] and chronic myelomonocytic leukemia (CMML) [7, 8], which is associated with a higher risk of disease progression. Furthermore, CMML is characterized by a significant increase in the CD14 + + CD16 − classical monocyte fraction, which comprises ≥ 94% of the total monocytes. This parameter has been proposed as a rapid and efficient method to differentiate CMML from reactive monocytosis [9, 10]. In MF patients, monocytosis has been recognized as an independent prognostic factor associated with inferior survival [11]. The presence of monocytosis in MF may indicate an accelerated phase of the disease, suggesting a transition towards a more aggressive state [12]. Nevertheless, the specific roles and quantitative alterations of IMCs subpopulations in MF remain underexplored. Thus, the objective of the present study is to quantitatively assess circulating IMCs, including monocytic subpopulations, pDCs and mDCs in the peripheral blood (PB) of MF patients and compare these profiles with those observed in healthy control subjects. Moreover, the present study aims to evaluate the association between quantitative deviations in these cell subpopulations and clinical characteristics in myelofibrosis, encompassing prognostic risk stratification, splenomegaly, anemia, monocytosis, and mutational status. Materials and methods Patients and controls A total of 21 patients with MF who undergo treatment at MPN outpatient clinic at the Universidade Federal de São Paulo (UNIFESP, São Paulo, Brazil) were available to participate in the study. The study was approved by the local institutional review board and all patients gave their informed consent prior to entering the study, in line with the guidelines of the local ethics committees and the Declaration of Helsinki. In parallel, 12 PB samples from an age and sex-matched group of adult healthy volunteers were studied as normal controls. Diagnosis of myelofibrosis was established according to the World Health Organization (WHO) criteria based on clinical data, megakaryocytic characteristics and reticulin fibrosis grade on BM biopsy and cytogenetic and molecular (JAK2, CALR and MPL) studies, after excluding BCR::ABL1–positive chronic myeloid leukaemia, polycythaemia vera, essential thrombocythaemia, myelodysplastic syndromes and other myeloid neoplasms [1]. Disease risk assessment was evaluated by the Dynamic International Prognostic Scoring System (DIPSS plus) for primary MF (PMF) and by MYSEC prognostic model for secondary MF (SMF) [13, 14]. Immunophenotypic studies All PB samples were collected in tubes containing K3 EDTA as anticoagulant. Cells in suspension (2 × 106 cells in 50–100 µL per tube) from the PB samples were stained with monoclonal antibodies (MAb) directed against cell surface markers using a stain-lyse-and-then-wash, direct immunofluorescence technique, as previously described [15]. Two tubes of 3-color combinations of Mabs — fluorescein isothiocyanate (FITC)/phycoerythrin (PE)/peridinin chlorophyll protein (PerCP-Cy5.5) — was used in all cases: tube 1: CD45/CD123/HLA-DR; and tube 2: CD16/CD14/CD11c. The source of MAbs was as follows: Ig isotype controls, CD45 (clone HI30), CD123 (clone 9F5), HLA-DR (clone L243), CD16 (clone 3G8), CD14 (clone M5E2), CD11c (clone B-ly6) were from Becton Dickinson Biosciences (BDB, San José, CA, USA). Data acquisition was performed immediately after completion of sample staining, using a FACSCanto II flow cytometer and the Diva software (BDB). For each sample, data from at least 1 × 105 events per tube was acquired. The Infinicyt software (Cytognos, SL, Salamanca, Spain) was used for the analysis of flow cytometry data. Daily instrument quality control was performed using CST beads (BDB) to ensure consistent determination of fluorescence intensity during the study. Plasmacytoid dendritic cells were identified by the expression of high intensity CD123 and moderate intensity CD45 (Fig. 1B). The expression of HLA-DR allowed the separation of pDCs (CD123+/HLA-DR+) from basophils (CD123+/HLA-DR-). Representative dot plots illustrating the different flow cytometry gating strategies used for the identification and quantification of monocytic subpopulations and myeloid and plasmacytoid dendritic cells in healthy subjects and myelofibrosis patients. In panel A, side scatter (SSC) and the expression of CD11c and CD14 were used to distinguish myeloid dendritic cells (mDC, magenta) and monocytes. The monocytes were further divided based on CD14 and CD16 expression into classical monocytes (C-MO, dark blue, CD14pos/CD16neg), intermediate monocytes (I-MO, light blue, CD14pos/CD16pos), and non-classical monocytes (NC-MO, cyan, CD14dim/CD16pos); in panel B, pDCs are characterized by strong expression of CD123 and HLA-DR (purple) Monocytes were identified by their high expression of CD11c and intermediate forward and side light scattering characteristics (FSC and SSC). These cells were subsequently categorized into three distinct subsets: classical monocytes (C-MO), which are marked by high-intensity CD14 expression and lack of CD16; intermediate monocytes (I-MO), defined by moderate to high CD14 expression associated to CD16 co-expression; and non-classical monocytes (NC-MO), characterized by either absent or low-intensity CD14 expression and positive CD16 expression (Fig. 1A). Myeloid dendritic cells were identified by their strong expression of CD11c, intermediate FSC and SSC, and the absence of CD14 and CD16 expression. The relative (%) number of monocytes, mDCs and pDCs were quantified as percentage values of the total nucleated cells, and monocyte subsets were represented by the total number of monocytes. The calculation of absolute values was carried out through a dual-platform approach, employing WBC counts obtained by an automated hematological analyzer performed in the same PB sample submitted to flow cytometry studies. Since the number of mDCs and pDCs in PB is very small, the absolute values obtained by flow cytometry have been described as per/µL. Statistical methods Mean value and SD, median and range of all parameters under study were calculated using the IBM SPSS 19.0 software program (IBM Corp, Armonk, NY, USA) and JASP software 0.17.1 (University of Amsterdan). The Mann-Whitney U test was used to calculate the statistical significance of differences observed between groups due to the small sample size. P values < 0.05 were considered significant. Results Characteristic of patients The mean age of MF patients was 70.2 ± 9 years (median 71 years, range 47–86 years). There were 11 males and 10 females. The distribution of cases according to the WHO classification was as follows: PMF (n = 14) and SMF (MF post-essential thrombocythemia or MF post-polycythemia vera, n = 7). According to the risk assessment, 15 patients were classified as low and intermediate-1 risk (PMF-DIPSS plus: 10 cases and SMF-MYSEC: 5 cases) and 6 cases as intermediate-2 and high-risk MF (PMF-DIPSS plus: 4 and SMF-MYSEC: 2 cases). Hemoglobin levels ranged from 7 to 16.2 g/dL (median 12.3 g/dL), white blood cell counts ranged from 1.1 to 31 × 109 cells/L (median 9.49 × 109 cells/L), and platelet counts ranged from 26 to 1,326 × 109 cells/L (median 286 × 109 cells/L). Lactate dehydrogenase (LDH) levels ranged from 99 to 1,424 U/L, with a median value of 381 U/L. Cytogenetic analysis was performed in all patients: 9 (42.9%) had a normal karyotype, 2 (9.5%) showed abnormal karyotypes, and in 10 cases (47.6%) no metaphases were obtained. The two abnormal karyotypes identified were 48,XY,+8,del(9)(q13),+der(9)(?)[20] and 46,XX, del(13q)(q13q21)[10]. JAK2 V617F mutation was detected in 11 patients, followed by 5 cases of CALR mutation, 2 cases of MPL W515L mutation, 2 cases of triple-negative and one case was JAK2 negative, but with unknown status for CALR and MPL. Regarding treatment, 17 cases used hydroxyurea (HU), 1 erythropoietin (EPO), 1 thalidomide, and 2 were on watchful waiting. Although most patients presented with splenomegaly, none received JAK inhibitor therapy due to the unavailability of these drugs in the Brazilian public healthcare system (Sistema Único de Saúde – SUS), which was the primary source of care for the study population. Patient characteristics are listed in Table 1. Table 1Characteristic of patientsCharacteristicsPatientsNumber of patients, n.21Age, years (median, range)71 (47–86)Male sex, n. (%)11 (52.4%)Primary myelofibrosis, n. (%)14 (66.7%)Secondary myelofibrosis, n. (%)7 (33.3%)Splenomegaly, n. (%)13 (61.9%)Hemoglobin, g/dL (median, range)12.3 (7–16.2)WBC, 109/L (median, range)9.49 (1.08–31)Peripheral blasts, (median, range)0 (0–8)Neutrophils, 109/L (median, range)6.1 (0.47–24.3)Monocytes, 109/L (median, range)0.37 (0.06–3.47)Platelets, 109/L (median, range)286 (26 − 1,326)Lactate dehydrogenase, U/L (median, range)381 (99 − 1,424)Karyotype, n.21 Normal, n. (%)9 (42.9%) Abnormal, n. (%)2 (9.5%) No metaphases, n. (%)10 (47.6%)JAK2, n. (% on 21 evaluable patients)11 (52.4%)CALR, n. (% on 20 evaluable patients)5 (25%) Type 1, n.1 Type 2, n.2 CALR mutation subtype not available, n.2MPL, n. (% on 20 evaluable patients)2 (10%)Triple negative, n. (% on 20 evaluable patients)2 (10%)Fibrosis Grade Grade 2, n. (%)8 (38.1%) Grade 3, n. (%)13 (61.9%)Risk Prognostic Score (DIPSS-plus)14 Low and Intermediate-1, n. (%)10 (71.4%) Intermediate-2 and High, n. (%)4 (28.6%)Risk Prognostic Score (MYSEC)7 Low and Intermediate-1, n. (%)5 (71.4%) Intermediate-2 and High, n. (%)2 (28.6%)Anemia Hb > 10.5 g/dL, n. (%)15 (71.4%) Hb < 10.5 g/dL, n. (%)6 (28.6%) Characteristic of patients Quantification of pDCs in myelofibrosis MF patients showed a significant reduction in both the relative and absolute number of circulating pDCs compared to healthy individuals. The percentage of pDCs in peripheral blood in MF was 0.02% (0–0.17%) versus 0.13% (0.07–0.26%) in healthy individuals (p = 0.0001), while the absolute number of pDCs was 2.32/µL (0–19.38/µL) in myelofibrosis versus 8.98/µL (4.14–14.98/µL) in the normal group (p = 0.001) (Fig. 1; Table 2). Table 2Quantification of myeloid and plasmacytoid dendritic cells and monocytic subsets in peripheral blood of myelofibrosis patients and healthy subjectsMyelofibrosis(n = 21)Normal(n = 12)ppDC %0.02 (0–0.17)0.13 (0.07–0.26)p < 0.001 /µL2.32 (0–19.38)8.98 (4.14–14.98)p < 0.001mDCs %0.12 (0.03–0.59)0.33 (0.12–0.87)p < 0.001 /µL8.7 (1.4–136.88)20.91 (9.66–71.28)p < 0.001Monocytes %4.91 (0.44–10.45)7.185 (4.6–11.2)p = 0.018 /µL369.23 (4.752–1798)439.21 (260.83–750.6)p = 0.494Non-classical monocytes %9.17 (0.3–23.9)10.75 (6.7–21)p = 0.501 /µL46.5 (0.6–164.9)47.7 (25.5–157.6)p = 0.421Intermediate monocytes %12.5 (5.55–38.7)11.5 (3.52–27)p = 0.489 /µL60.7 (0.5–221.2)51.05 (20.4–97.6)p = 0.537Classical Monocytes %77.03 (42.8–89.63)74.2 (59.3–85.44)p = 0.501 /µL251.3 (3.3–1402.4)354.7 (176.4–496.3)p = 0.421The relative (%) number of cell populations was calculated by the total number of nucleated cells. The absolute number of cell subsets was determined using a hematological analyzer performed on the same sample submitted to flow cytometry studies Quantification of myeloid and plasmacytoid dendritic cells and monocytic subsets in peripheral blood of myelofibrosis patients and healthy subjects The relative (%) number of cell populations was calculated by the total number of nucleated cells. The absolute number of cell subsets was determined using a hematological analyzer performed on the same sample submitted to flow cytometry studies The reduction in pDCs was even more pronounced in subgroups of MF patients with specific clinical features (Table 3). For patients with anemia (Hb < 10.5 g/dL), the median percentage of pDCs was 0.0% compared to 0.04% in those without anemia (p = 0.028), and the absolute number was 0.0/µL versus 3.64/µL (p = 0.04). In cases of splenomegaly, pDCs were reduced to 0.01% compared to 0.085% (p = 0.004), and the absolute count was 1.45/µL versus 6.48/µL (p = 0.005). Additionally, patients with different grades of bone marrow fibrosis also showed significant reductions: 0.01% vs. 0.085% (p < 0.001) and 0.98/µL vs. 6.5/µL (p < 0.001) (Fig. 4). Table 3Quantification of myeloid and plasmacytoid dendritic cells and monocytic subsets in peripheral blood of myelofibrosis patients according to the presence of anemia, splenomegaly, JAK2 mutation status and prognostic risk classificationSplenomegalyAnemiaJAK-2 V617FRisk classificationPresent(n = 13)Absent(n = 8)< 10.5 g/dL(n = 6)> 10.5 g/dL(n = 15)Mutated(n = 11)Non-mutated(n = 10)Low risk(n = 15)High risk(n = 6)pDC %0.01**(0–0.07)0.08**(0.01–0.17)0*(0–0.02)0.04*(0–0.17)0.02(0–0.09)0.02(0–0.17)0.02(0–0.17)0.005(0–0.07) /µL1.45**(0–5.15)6.48**(0.98–19.38)0*(0–2.32)3.64*(0–19.38)2.78(0–6.77)2.2(0–19.38)3.56(0–19.38)0.72(0–4.5)mDCs %0.1(0.03–0.59)0.16(0.03–0.24)0.11(0.05–0.59)0.12(0.03–0.24)0.08(0.03–0.2)0.14(0.05–0.59)0.12(0.03–0.59)0.1(0.05–0.2) /µL7.69(1.404–136.88)11.04(3.9–24.96)5.83(1.40–136.88)9.12(3.9–24.96)7.69(2.02–22.24)11.68(1.4–136.88)9.12(3.9–136.88)5.83(1.4–22.24)MO %2.93(0.44–10.45)5.34(3.06–8.98)6.65(0.44–10.45)4.43(0.7–8.98)3.06(0.7–10.45)6.65(0.44–8.98)4.91(1.08–8.98)4.55(0.44–10.45) /µL301.79(4.75–1798)601.22(228.9–948.6)453.96(4.75–1798)362.1(155.87–948.6)333.47(155.87–948.6)633.89(4.752–1798)369.23(155.87–1798)308.39(4.75–540.12)NC-MO %7.5(0.3–23.9)12.75(5.700–22.89)8.33(3.14–22.8)10.58(0.3–23.9)9.07(0.3–23.9)10.585(3.86–22.89)9.17(1.08–23.9)12.75(0.3–22.8) /µL21.1(0.6–164.9)55.55(46.5–100)34.45(0.9–164.9)52.4(0.6–100)21.1(0.6–97.2)46.5(0.9–164.9)52.4(3.6–164.9)22.9(0.6–97.2)I-MO %12.5(7.77–31.6)12.07(5.55–38.7)11.6(7.85–19.67)12.96(5.55–38.7)19.67*(7.77–38.7)10.69*(5.55–17.64)12.7(5.55–38.7)11.7(7.77–20) /µL60.7(0.5–221.2)68.35(40.4–140.1)70.55(0.5–221.2)53.4(14.4–140.1)71.4(14.4–140.1)50.45(0.5–221.2)63.1(14.4–221.2)38.1(0.5–108)C-MO %77.03(54.5–89.63)76(42.8–88.5)77.515(63.19–88.28)75.360(42.8–89.63)75.360(42.8–89.63)78(59.2–88.5)78(42.8–88.5)73.4(62–89.63) /µL239.9(3.3–1402)480.55(135.5–744.3)356.9(3.3–1402)239.9(108.68–744.3)174.4(108.68–744.3)519.3(3.3–1402)251.3(108.7–1402)249.8(3.3–388.6)Results in bold indicate statistical significance (* p < 0.05, ** p < 0.01) Quantification of myeloid and plasmacytoid dendritic cells and monocytic subsets in peripheral blood of myelofibrosis patients according to the presence of anemia, splenomegaly, JAK2 mutation status and prognostic risk classification 0.01** (0–0.07) 0.08** (0.01–0.17) 0* (0–0.02) 0.04* (0–0.17) 0.02 (0–0.09) 0.02 (0–0.17) 0.02 (0–0.17) 0.005 (0–0.07) 1.45** (0–5.15) 6.48** (0.98–19.38) 0* (0–2.32) 3.64* (0–19.38) 2.78 (0–6.77) 2.2 (0–19.38) 3.56 (0–19.38) 0.72 (0–4.5) 0.1 (0.03–0.59) 0.16 (0.03–0.24) 0.11 (0.05–0.59) 0.12 (0.03–0.24) 0.08 (0.03–0.2) 0.14 (0.05–0.59) 0.12 (0.03–0.59) 0.1 (0.05–0.2) 7.69 (1.404–136.88) 11.04 (3.9–24.96) 5.83 (1.40–136.88) 9.12 (3.9–24.96) 7.69 (2.02–22.24) 11.68 (1.4–136.88) 9.12 (3.9–136.88) 5.83 (1.4–22.24) 2.93 (0.44–10.45) 5.34 (3.06–8.98) 6.65 (0.44–10.45) 4.43 (0.7–8.98) 3.06 (0.7–10.45) 6.65 (0.44–8.98) 4.91 (1.08–8.98) 4.55 (0.44–10.45) 301.79 (4.75–1798) 601.22 (228.9–948.6) 453.96 (4.75–1798) 362.1 (155.87–948.6) 333.47 (155.87–948.6) 633.89 (4.752–1798) 369.23 (155.87–1798) 308.39 (4.75–540.12) 7.5 (0.3–23.9) 12.75 (5.700–22.89) 8.33 (3.14–22.8) 10.58 (0.3–23.9) 9.07 (0.3–23.9) 10.585 (3.86–22.89) 9.17 (1.08–23.9) 12.75 (0.3–22.8) 21.1 (0.6–164.9) 55.55 (46.5–100) 34.45 (0.9–164.9) 52.4 (0.6–100) 21.1 (0.6–97.2) 46.5 (0.9–164.9) 52.4 (3.6–164.9) 22.9 (0.6–97.2) 12.5 (7.77–31.6) 12.07 (5.55–38.7) 11.6 (7.85–19.67) 12.96 (5.55–38.7) 19.67* (7.77–38.7) 10.69* (5.55–17.64) 12.7 (5.55–38.7) 11.7 (7.77–20) 60.7 (0.5–221.2) 68.35 (40.4–140.1) 70.55 (0.5–221.2) 53.4 (14.4–140.1) 71.4 (14.4–140.1) 50.45 (0.5–221.2) 63.1 (14.4–221.2) 38.1 (0.5–108) 77.03 (54.5–89.63) 76 (42.8–88.5) 77.515 (63.19–88.28) 75.360 (42.8–89.63) 75.360 (42.8–89.63) 78 (59.2–88.5) 78 (42.8–88.5) 73.4 (62–89.63) 239.9 (3.3–1402) 480.55 (135.5–744.3) 356.9 (3.3–1402) 239.9 (108.68–744.3) 174.4 (108.68–744.3) 519.3 (3.3–1402) 251.3 (108.7–1402) 249.8 (3.3–388.6) Results in bold indicate statistical significance (* p < 0.05, ** p < 0.01) Distribution of plasmacytoid dendritic cells (pDCs) in relation to splenomegaly (A), bone marrow fibrosis (B), anemia (C) and JAK2 mutation (D). Each plot includes a scatter plot, box plot, and one-sided violin plot (raincloud plot) representing the distribution of values. The p-values indicate statistically significant differences for some of the clinical features Although patients with intermediate-2 and high-risk prognostic scores had fewer pDCs, there was no significant difference between these risk groups (p = 0.09). Similarly, no statistical differences in pDC numbers were observed in relation to age, JAK2 mutational status and the use of myelosuppressive therapy with hydroxyurea. Quantification of mDCs in myelofibrosis Myeloid dendritic cells (mDCs) also showed marked differences between patients with myelofibrosis and healthy individuals (Fig. 2). In MF patients, the percentage of mDCs was significantly lower, with a median value of 0.12% (0.03–0.59%), compared to the normal group, which had a median percentage of 0.33% (0.12–0.87%) (p < 0.001). Similarly, the absolute count of mDCs per microliter was markedly reduced in the myelofibrosis group, with a median of 8.7/µL (1.4–136.88), as opposed to the normal cohort, which had a median count of 20.91/µL (9.66–71.28/µL) (p < 0.001). Despite this, within the MF cohort, the quantification of mDCs was not influenced by variables such as patient age, presence of JAK2 mutation, administration of hydroxyurea, BM fibrosis, risk classification or the occurrence of anemia and splenomegaly. Raincloud plots showing the percentage (left panel) and absolute count per microliter (right panel) of plasmacytoid dendritic cells (A) and myeloid dendritic cells (B) in patients with myelofibrosis (MF) and normal controls. Each dot represents an individual subject. The box plots show the median, interquartile range, and 1.5 times the interquartile range. The one-sided violin plot display the distribution of the data. The p-values indicate statistically significant differences between the groups for each dendritic cell subset Quantification of monocytic subpopulations in myelofibrosis Regarding the quantification of the total number of monocytes and their subpopulations, there was no statistical difference between patients with MF and healthy individuals, except for the percentage of total monocytes, which was slightly reduced in MF: 4.91% (0.44–10.45%) vs. 7.18% (4.6–11.2%) (p = 0.018) (Table 2). The distribution of monocyte subpopulations was similar between the MF cases and the normal control group (Fig. 3). Distribution of monocyte subsets in myelofibrosis (MF) and normal controls. (A) Comparison of classical monocytes (C-MO), intermediate monocytes (I-MO), and non-classical monocytes (NC-MO) as a percentage of total monocytes between MF patients and normal controls. (B) Comparison of absolute counts of C-MO, I-MO, and NC-MO between MF patients and normal controls. Each plot includes a scatter plot, box plot, and one-sided violin plot (raincloud plot) representing the distribution of values. The p-values indicate no statistically significant differences between the groups for each monocyte subset In MF patients, the distribution of monocytes and subsets was also similar concerning age, anemia, splenomegaly, degree of fibrosis, risk classification and treatment. However, patients with JAK2 mutation exhibit a higher concentration of cells in the I-MO compartment: 19.67% (7.77–38.7%) versus 10.69% (5.55–17.64%) (p = 0.01), although there was no difference in absolute number. Four MF cases presented absolute monocytosis (> 1 × 109/L) and five cases presented olygomonocytosis (0.5–1 × 109/L) detected by complete blood count. The distribution of monocytic subpopulations was similar between patients with and without monocytosis; C-MO: 74% (42.8–89.6%) vs. 78.2% (78–88.2%); I-MO: 12.9% (5.5–38.7%) vs. 10.7% (7.8–12.3%); and NC-MO: 10.58% (0.3–23.9%) vs. 9.12% (3.8–12%) (p > 0.05); and between cases with and without olygomonocytosis: C-MO: 74% (42.8–89.6%) vs. 78.2% (78–88.2%); I-MO: 12.9% (5.5–38.7%) vs. 10.7% (7.8–12.3%); and NC-MO: 10.58% (0.3–23.9%) vs. 9.12% (3.8–12%) (p > 0.05) (Fig. 4). Discussion The current study aimed to quantitatively assess circulating innate myeloid cells, including pDCs, mDCs and monocytic subpopulations, in the PB of MF patients compared to healthy controls using a simplified flow cytometry strategy. Our findings demonstrate a significant reduction in both the relative and absolute numbers of dendritic cells in MF patients, with further reductions of pDCs observed in patients with grade 3 fibrosis, anemia and splenomegaly. In contrast, the distribution of monocyte subpopulations did not significantly differ between MF patients and healthy controls. These findings suggest that reductions in circulating dendritic cells, especially pDCs, may correlate with clinical features of more advanced disease, including grade 3 fibrosis, anemia, and splenomegaly. Such associations highlight the potential utility of mDC and pDC quantification as surrogate markers of disease severity or progression in MF. Although our study was not powered to explore all clinical correlations due to the limited sample size, the observed trends provide a rationale for future investigations into their prognostic significance. Moreover, the small cohort size may have limited the ability to detect statistically significant differences in other immune cell subsets. MF is characterized by progressive marrow fibrosis and alterations in the bone marrow microenvironment. These fibrotic changes may disrupt the normal hematopoietic niche, affecting the development, survival, or migration of dendritic cells [16–18]. Additionally, imbalances in cytokine signaling pathways [19], particularly those involved in regulating dendritic cell development and function, could contribute to the reduction of mDCs and pDCs in MF. Dysregulated cytokine production, such as elevated levels of TGF-β or IL-6, commonly observed in MF [20–22], may suppress pDC differentiation or survival [23–25]. Romano et al. also observed the reduction of circulating mDCs and pDCs in MF, associating this decrease with the compromised ability of MF-derived monocytes to differentiate into DCs upon in vitro stimulation with IL-4 and GM-CSF [26]. The association of splenomegaly with even lower levels of pDCs indicates that increased splenic sequestration may also explain their reduction [27]. Although the use of myelosuppressive agents may have direct or indirect effects on the quantification of IMC populations, our data did not show any influence of hydroxyurea on the quantification of mDCs and pDCs. However, it is important to note that JAK inhibitors, unlike hydroxyurea, can modulate both innate and adaptive immune responses by interfering with the JAK-STAT signaling pathway. This modulation may lead to significant immunosuppressive effects, including alterations in dendritic cell function and number, as previously demonstrated in the literature [28–31]. Myelofibrosis has been associated with various conditions, including viral infections [32], autoimmune disorders [33, 34], and development of second malignancies [35, 36]. The reduction of DCs in MF may play a significant role in these associations. pDCs are essential for antiviral immunity, primarily through the production of type I interferons (IFNs) in response to viral infections [37]. The reduction of mDCs and pDCs in MF may compromise the ability of the immune system to mount an effective antiviral response, increasing the susceptibility of patients to viral infections and potentially leading to more severe or prolonged illnesses [38]. In addition, reductions in dendritic cells numbers may disrupt the balance of immune responses and surveillance mechanisms, leading to dysregulated inflammation, autoimmunity, or impaired immune tolerance in MF patients, besides allowing for the proliferation and survival of malignant cells and contributing to disease progression [39–41]. The reduction of pDCs in MF may have implications for the development and efficacy of immunotherapeutic approaches, including strategies targeting immune checkpoint pathways or harnessing dendritic cell-based vaccines. Understanding the impact of mDC and pDC alterations on the immune landscape in MF could inform the design of novel immunotherapeutic strategies tailored to restore immune homeostasis and enhance antitumor immunity [42]. The lack of significant differences in monocytic subpopulations between MF patients and healthy controls, apart from the increase of I-MO in JAK2 mutated MF cases, might indicate that the role of these cells in MF pathophysiology is less pronounced or requires further elucidation under specific clinical conditions. The increased frequency of I-MO was also observed by other groups and was associated with positivity for JAK2 [43–45]. Nevertheless, the assessment of monocytic subpopulations in MF can be very useful in certain clinical situations, especially in the presence of monocytosis [46, 47]. CMML and MF with monocytosis can present overlapping features, as JAK2 mutation and bone marrow fibrosis, making their differential diagnosis challenging. In these situations, our findings suggest that the presence of less than 94% classical monocytes supports the diagnosis of MF with monocytosis rather than CMML, as appointed by others [44]. Our study has some limitations, as the small sample size and the single-center design, which may affect the generalizability of the findings. Additionally, while significant differences in mDC and pDC numbers were observed, the functional implications of these cells in MF remain unclear, necessitating further studies to elucidate their role in the disease mechanism. Another limitation is that all included patients had overt fibrotic-stage primary myelofibrosis. As bone marrow fibrosis grade > 2 is recognized as an adverse prognostic factor in PMF—independent of other variables, as reflected in the MIPSS70 model [48]—the lack of patients in the pre-fibrotic stage prevents comparison of dendritic cell subsets across disease phases. Future studies including pre-fibrotic cases will be important to determine whether pDC distribution differs between early and advanced stages of PMF. Future research should focus on larger, multicenter studies to validate the findings and enhance their applicability across diverse populations. Additionally, investigating the functional roles of mDCs and pDCs and their interaction with other components of the immune system in MF could provide deeper insights into their contributions to disease pathogenesis. Longitudinal studies assessing changes in IMC profiles in response to different therapeutic interventions could also be valuable. In conclusion, this study provides novels insights into the alterations of innate myeloid cells in myelofibrosis. These findings not only enhance our understanding of the immune landscape in MF but also propose potential diagnostic and therapeutic targets that warrant further exploration. By linking cellular profiles with clinical presentation and outcomes, this research adds valuable knowledge to the complex interplay between the immune system and myeloproliferative neoplasms. Author contributions N.A.C.S. and A.F.S. conceptualized the study and wrote the main manuscript text. N.A.C.S., F.P.G., and M.C.R.B. performed the immunophenotypic studies. D.O.B., L.C.V., and A.F.S. evaluated the patients and collected clinical data. All authors reviewed and approved the final manuscript. Funding No funding was received for conducting this study. Data availability No datasets were generated or analysed during the current study. Declarations Ethical approval The study was approved by the institutional review board of the Universidade Federal de São Paulo, and all patients gave their informed consent prior to entering the study. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.